PMID: 6105436Aug 9, 1980Paper

Early intravenous atenolol treatment in suspected acute myocardial infarction. Preliminary report of a randomised trial

Lancet
S YusufP Sleight

Abstract

214 patients were studied in a randomised trial to determine whether administraiton of intravenous atenolol within 12 hours of chest pain reduced eventual infarct size, as estimated by cumulative enzyme release and by ECG changes. 135 patients already had ECG evidence of infarction at entry; 72 received atenolol which significantly decreased subsequent enzyme release (atenolol and control means = 121 IU, SE +/- 10 and 177 IU, SE +/- 17; 2p < 0.005) and enhanced R-wave preservation (atenolol and control means = 46% +/- 3 and 36% +/- 3; 2p < 0.02). 79 patients had no evidence of infarction at entry; 44 did not receive atenolol and 27 of these subsequently developed infarction, whereas only 11 of 35 treated patients infarcted during their hospital stay (2p < 0.01). In hospital, fewer atenolol patients died (4 vs 9), had non-fatal cardiac arrests (2 vs 6), or required therapy for heart-failure (36 vs 47). Unlike many previous trials which had negative results, in this trial we gave the drug intravenously and promptly (median of 4 hours from onset of pain to injecton), thereby achieving early beta-blockade.

References

May 1, 1977·Progress in Cardiovascular Diseases·R P Holland, M F Arnsdorf
Sep 1, 1979·British Heart Journal·S YusufP Sleight
May 18, 1968·British Medical Journal·R M NorrisP J Scott
Oct 1, 1972·Circulation·B E SobelR D Yoder
Jan 1, 1971·Circulation·W B Hood

❮ Previous
Next ❯

Citations

May 1, 1992·Journal of Clinical Pharmacology·L M PrisantM J Frank
Jan 1, 1983·European Journal of Clinical Pharmacology·B SilkeS H Taylor
Jan 1, 1987·Research in Experimental Medicine. Zeitschrift Für Die Gesamte Experimentelle Medizin Einschliesslich Experimenteller Chirurgie·R SeitzR Egbring
May 1, 1983·Irish Journal of Medical Science·B SilkeS H Taylor
Oct 14, 1983·European Journal of Pharmacology·V S MurthyD H Schmidt
Jan 1, 1983·Pharmacology & Therapeutics·A J Scriven, P J Lewis
Apr 2, 1981·The New England Journal of Medicine·P Sleight
Aug 13, 1981·The New England Journal of Medicine
Jun 17, 1982·The New England Journal of Medicine·W H Frishman
Aug 19, 1982·The New England Journal of Medicine·R M Norris
Nov 18, 1982·The New England Journal of Medicine·S H TaylorD M Burley
Dec 8, 1983·The New England Journal of Medicine·M J BrownM B Murphy
Jan 5, 1984·The New England Journal of Medicine·UNKNOWN International Collaborative Study Group
May 16, 1981·British Medical Journal·J R Mitchell
Mar 6, 1982·British Medical Journal·M C Petch
Jun 12, 1982·British Medical Journal·N S Baber, J A Lewis
May 1, 1981·British Heart Journal·J H JürgensenO Pedersen-Bjergaard
Feb 1, 1983·British Heart Journal·D A Chamberlain
Mar 1, 1983·British Heart Journal·D M BoyleR G Shanks
Apr 1, 1984·British Heart Journal·J HerlitzL Wilhelmsen
Jan 1, 1985·British Heart Journal·W Kübler, A Doorey
Jun 1, 1983·Journal of Clinical and Hospital Pharmacy·M J Kendall, S R Smith
Sep 1, 1982·Journal of Clinical and Hospital Pharmacy·P L Weissberg
Jan 1, 1985·Clinical and Experimental Hypertension. Part A, Theory and Practice·V DeQuattro, R Hamad
Apr 8, 2016·Journal of the American College of Cardiology·Robert A Kloner, Eugene Braunwald
Jan 24, 2007·American Heart Journal·Stéphane RinfretLouise Pilote

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.